Skip to main content
SpringerLink
Log in
Book cover

Antibody-Drug Conjugates and Immunotoxins

From Pre-Clinical Development to Therapeutic Applications

  • Book
  • © 2013

Overview

Editors:
  1. Gail Lewis Phillips

    1. South San Francisco, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  • Features up-to-date research
  • Provides an exhaustive review of anti-body drug conjugate and immunotoxin targets
  • Explores new technologies for site-specific conjugation

Part of the book series: Cancer Drug Discovery and Development (CDD&D)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (19 chapters)

  1. Front Matter

    Pages i-ix
    Download chapter PDF

  2. Introduction and Development Perspectives

    1. Front Matter

      Pages 1-1
      Download chapter PDF

    2. Antibody Directed Delivery for Treatment of Cancer: Antibody Drug Conjugates and Immunotoxins

      • Pamela A. Trail
      Pages 3-22

    3. Antibody–Drug Conjugate Development

      • Aakanksha Khandelwal, Haleh Saber, Marjorie A. Shapiro, Hong Zhao
      Pages 23-38

  3. Development of Antibody-Drug Conjugates

    1. Front Matter

      Pages 39-39
      Download chapter PDF

    2. Assay Methodologies and Challenges

      • Katherine R. Kozak, Helga Raab
      Pages 41-56

    3. Clinical Pharmacology Strategies in the Development of Antibody–Drug Conjugates

      • Sandhya Girish, Manish Gupta
      Pages 57-75

    4. Predictive Biomarkers for Antibody–Drug Conjugates

      • David Dornan, Jeff Settleman
      Pages 77-90

  4. Selection of Cytotoxic Agents

    1. Front Matter

      Pages 91-91
      Download chapter PDF

    2. Factors Involved in the Design of Cytotoxic Payloads for Antibody–Drug Conjugates

      • Wayne C. Widdison, Ravi V. J. Chari
      Pages 93-115

    3. Linker Technology and Impact of Linker Design on ADC Properties

      • Victor S. Goldmacher, Rajeeva Singh, Thomas Chittenden, Yelena Kovtun
      Pages 117-135

  5. Antibody-Drug Conjugates for Hematologic Malignancies

    1. Front Matter

      Pages 137-137
      Download chapter PDF

    2. Antibody–Drug Conjugates for the Treatment of B-Cell Malignancies

      • Andrew G. Polson
      Pages 139-147

    3. Targeting CD19 with SAR3419, an anti-CD19-Maytansinoid Conjugate for the Treatment of B Cell Malignancies

      • John M. Lambert, Veronique Blanc, Nathalie Le Bail, Anne Bousseau
      Pages 149-160

    4. Brentuximab Vedotin (SGN-35) for CD30-Positive Malignancies

      • Andres Forero, Christos Vaklavas, Albert F. LoBuglio
      Pages 161-175

  6. Antibody-Drug Conjugates for Solid Tumors

    1. Front Matter

      Pages 177-177
      Download chapter PDF

    2. Trastuzumab Emtansine (T-DM1) for the Treatment of HER2-Positive Cancer with a Focus on Breast Cancer

      • Hope S. Rugo, Ian E. Krop, Yu-Waye Chu
      Pages 179-210

    3. CDX-011 (Glembatumumab Vedotin, CR011-vcMMAE)

      • Christos Vaklavas, Albert F. LoBuglio, Mansoor Saleh, Michael Yelin, Andres Forero
      Pages 211-220

    4. Case Study: An Antibody–Drug Conjugate Targeting MUC16 for Ovarian Cancer

      • Douglas Leipold, William G. Mallet
      Pages 221-239

    5. EphA2 Immunoconjugate

      • Zhan Xiao, Dowdy Jackson, David A. Tice
      Pages 241-253
Back to top

Keywords

About this book

This volume gathers the leading research on antibody-drug conjugates and immunotoxins. Following a rigorous overview, the volume delves into focused sections on all aspects of ADCs and ITs from clinical development through to targeted therapeutic applications and the latest technologies.

Editors and Affiliations

  • South San Francisco, USA

    Gail Lewis Phillips

Bibliographic Information

  • Book Title: Antibody-Drug Conjugates and Immunotoxins

  • Book Subtitle: From Pre-Clinical Development to Therapeutic Applications

  • Editors: Gail Lewis Phillips

  • Series Title: Cancer Drug Discovery and Development

  • DOI: https://doi.org/10.1007/978-1-4614-5456-4

  • Publisher: Humana New York, NY

  • eBook Packages: Medicine, Medicine (R0)

  • Copyright Information: Humana Press 2013

  • Hardcover ISBN: 978-1-4614-5455-7Published: 12 December 2012

  • Softcover ISBN: 978-1-4899-9700-5Published: 28 January 2015

  • eBook ISBN: 978-1-4614-5456-4Published: 13 December 2012

  • Series ISSN: 2196-9906

  • Series E-ISSN: 2196-9914

  • Edition Number: 1

  • Number of Pages: X, 378

  • Topics: Cancer Research, Biomedicine general, Antibodies

Publish with us

Policies and ethics

Back to top

Search

Navigation